<
new post
StocksRunner logo
mail
search
 
menu
 
Cytokinetics Incorpo
$67.94
+0.16%
 
  Set Alerts  
  
  Overview  
  
  Comments  
  
  Insights  
  
     Risks     
  
  Rating  
  
     Chart     
  
  Analysts  
  
  Street  
  
  Sentiment  
  
  Headlines  
 

CYTK Stock Analysis & IQ Rating | Cytokinetics Incorpo

 
 

CYTK

 

Cytokinetics Incorpo

$67.94

 
+$0.11 | +0.16%
 
Set Alerts
 
  Overview  
  
  Comments  
  
  Insights  
  
     Risks     
  
  Rating  
  
     Chart     
  
  Analysts  
  
  Street  
  
  Sentiment  
  
  Headlines  
 
 
52W High
$70.98
 
 
MKT CAP
$8.44B
 
52W Low
$29.31
 
 
VOL
$2.00M
 
P/E Ratio
N/A
 
 
AVG VOL
$1.69M
 
RSI
59.28
 
 
TREND
Uptrend
 
 
 

CYTK Stock IQ

 
lock  Login to see Cytokinetics Incorpo (CYTK) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid
 
 

CYTK Target Price

 
 
 

Strengths

 
 

CYTK Rewards

 Upgraded on attractively valued

CYTK Rewards

 Earnings are forecast to grow

CYTK Rewards

 Outperform the market

 

Technical Indicators

 
 

CYTK Technical Indicators

 5+ Days Up

 
 

CYTK Price Performance

 
 

$63.19   (+7.52%)

$67.55   (+0.58%)

$53.89   (+26.07%)

$43.31   (+56.87%)

 
 
1year
6month
3month
1month

CYTK Analysts Opinion

Overall standing based on market and analyst consensus. menu Hover over the category for more information

Earnings

×

Earnings

CYTK Earnings Sentiment Above analyst estimates

Rating

×

Rating

CYTK Rating Sentiment Upgraded on attractively valued

Momentum

×

Momentum

CYTK Momentum Analysis Has been gaining momentum

Activity

×

Activity

Future

×

Future

CYTK Future Sentiment Earnings are forecast to grow
CYTK Future Sentiment Outperform the market
CYTK Analysts Opinion

CYTK Analysts opinion is positive and also has improved from the past 3 months

CYTK Street Sentiment

Analysts perspectives on the stock desirability, trend direction and growth potential

100%
Consensus Rating
100%
Buy
Opinion
100%
Trend
Score
100%
Potential
Score
CYTK Street Sentiment

CYTK Street Sentiment is extremely bullish and have positive views on the near-term outlook

CYTK Risk Level

CYTK has Low risk level

CYTK Risk Level
Low
LOW
HIGH

CYTK Performance Sentiment

Sentiments overview associated with events and the stock performance

100%
Positive
6 out of 6
events present
0%
Negative
0 out of 6
events present
Very Bullish
Bullish
Neutral
Bearish
Very Bearish

Key Price Levels

Average key support and resistance price levels

Support Price
$60.24
Resistance Price
$67.94
Current Price Range
$67.94
$60.24
$67.94
Show methods +
 
 

Analyst Consensus

 

Recent Upgrades and Downgrades

 
 
89%
Consensus Rating
STRONG BUY
8
Buy
1
Hold
0
Sell
Date
Action
Rating
Firm

Feb 19, 2026

 

Initiate

 

Buy

 

B. Riley

 

Dec 24, 2025

 

Reiterate

 

Overweight

 

Morgan Stanley

 

Dec 23, 2025

 

Reiterate

 

Outperform

 

Citizens

 

Dec 23, 2025

 

Reiterate

 

Outperform

 

RBC

 

Dec 23, 2025

 

Reiterate

 

Overweight

 

Barclays

 
 
 
Runners Also Watch
Close Price
Change
 

NVO

Novo Nordisk A/S

47.42

-2.13%

 

AZN

Astrazeneca

204.20

-1.09%

 
 
 
CYTK Latest Analysis +
 
 
FAQ About CYTK Stock Insights
 

What is CYTK current stock price?

What are CYTK stock strengths?

What is CYTK Risk Level?

What is CYTK market cap and volume?

What is CYTK current Stock IQ?

Should I buy CYTK stock right now?

Is CYTK a Strong Buy right now?

What does a 'Strong Buy' rating mean for CYTK?

What does a 'Strong Sell' rating mean for CYTK?

What factors influence CYTK's Stock IQ?

 
 
StocksRunner

Explore our CYTK Stock insights

  • In-Depth Market Analysis and Trends
  • Expert Insights on Market Dynamics
  • Tailored CYTK Stock Strategies
  • Effective Risk Management
 

FIND US ON

StocksRunner on Facebook StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss
 

Receive our CYTK Daily Alerts

Join our subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

 
Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

 
Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

 
Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

 
About StocksRunner

Log In

Sign Up

Plans & Pricing

Contact Us

Terms of use

Privacy Policy

 
 
 
 

CYTK

 

Cytokinetics Incorpo

 
Set Alerts
 
 

Current Price

 

$67.94

 
+$0.11 | +0.16%
 
 
52W High
$70.98
 
 
MKT CAP
$8.44B
 
52W Low
$29.31
 
 
VOL
$2.00M
 
P/E Ratio
N/A
 
 
AVG VOL
$1.69M
 
RSI
59.28
 
 
TREND
Uptrend
 
 
 
  Overview  
  
  Comments  
  
  Insights  
  
   Risks   
  
  Rating  
  
  Chart  
  
  Analysts  
  
  Street  
  
  Sentiment  
 
 
 

Runners Also Watch

 
 
 
Symbol
Close
Change
 

NVO

Novo Nordisk A/S

47.42

-2.13%

 

AZN

Astrazeneca

204.20

-1.09%

 
 
 
 
 
user
 
 
 
 

CYTK Price Performance

 
 

$63.19   (+7.52%)

$67.55   (+0.58%)

$53.89   (+26.07%)

$43.31   (+56.87%)

 
 
1year
6month
3month
1month
 

CYTK Analysts Opinion

Overall standing per market and analyst expectations. menu Hover over the category for more information

Earnings

×

Earnings

CYTK Earnings Sentiment Above analyst estimates

Rating

×

Rating

CYTK Rating Sentiment Upgraded on attractively valued

Momentum

×

Momentum

CYTK Momentum Sentiment Has been gaining momentum

Activity

×

Activity

Future

×

Future

CYTK Future Sentiment Earnings are forecast to grow
CYTK Future Sentiment Outperform the market
CYTK Analysts Opinion

CYTK Analysts opinion is positive and also has improved from the past 3 months

CYTK Street Sentiment

Analysts perspectives on the stock desirability, trend direction and growth potential

100%
Consensus Rating
100%
Buy
Opinion
100%
Trend
Score
100%
Potential
Score
CYTK Street Sentiment

CYTK Street Sentiment is extremely bullish and have positive views on the near-term outlook

CYTK Risk Level

CYTK has Low risk level

CYTK Risk Level
Low
LOW
HIGH
CYTK Performance Sentiment
Sentiments overview associated with events and the stock performance.
100%
Positive
6 out of 6
events present
0%
Negative
0 out of 6
events present
Very Bullish
Bullish
Neutral
Bearish
Very Bearish

Key Price Levels

Average key support and resistance price levels

Support Price
$60.24
Resistance Price
$67.94
Current Price Range
$67.94
$60.24
$67.94
Show methods +

Latest Analyst Actions

Overall Wall Street Rating

89%
Consensus Rating
STRONG BUY
8
Buy
1
Hold
0
Sell
Date
Action
Rating
Firm
Feb 19, 2026
Initiate
Buy
B. Riley
Dec 24, 2025
Reiterate
Overweight
Morgan Stanley
Dec 23, 2025
Reiterate
Outperform
Citizens
Dec 23, 2025
Reiterate
Outperform
RBC
Dec 23, 2025
Reiterate
Overweight
Barclays
 
 
 
 

CYTK Stock IQ

 
 
 
lock  Login to unlock Cytokinetics Incorpo (CYTK) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid
 
 
 

Target Price

 
 
 
 
 
 
 

Stock Insights

 
 
 
 

Strengths

 
 

CYTK Rewards

 Upgraded on attractively valued

CYTK Rewards

 Earnings are forecast to grow

CYTK Rewards

 Outperform the market

 

Technical Indicators

 
 

CYTK Technical Indicators

 5+ Days Up

 
 
 

CYTK Latest Analysis

 
 
 

Cytokinetics Incorporated (CYTK) Poised for Market Share Gain with Myqorzo in Cardiac Myosin Space. Cytokinetics (NASDAQ:CYTK) is one of the best debt-free mid-cap stocks to buy according to hedge funds. On February 4 B. Riley initiated coverage of Cytokinetics (NASDAQ:CYTK) with a Buy rating and a $108 price target. The positive stance underscores the research firms confidence about the companys ability to capture market share in the cardiac myosin [….]

 

Thu Feb 19, 2026

$67.83 | +1.27%
 
Rating

Cytokinetics Wins EU Approval for Cardiovascular Drug Myqorzo . CYTK secures EU approval for Myqorzo in symptomatic obstructive HCM expanding its first commercial drug across major global markets.

 

Wed Feb 18, 2026

$66.98 | +0.54%
 
Activity

Truist Notes Operational Investments For Cytokinetics Incorporated (CYTK) to Support Short-Term Growth. Cytokinetics Incorporated (NASDAQ:CYTK) is among the 15 Innovative Healthcare Stocks to Buy According to Analysts. Cytokinetics Incorporated (NASDAQ:CYTK) is one of the fifteen best healthcare stocks on our list. TheFly reported on February 3 that Truist raised its price target on CYTK to $92 from $84 and maintained a Buy rating. The company revised its model ahead of its Q4 [….]

 

Wed Feb 18, 2026

$66.98 | +0.54%
 
Potential

Earnings Preview: Cytokinetics (CYTK) Q4 Earnings Expected to Decline. Cytokinetics (CYTK) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

 

Tue Feb 17, 2026

$66.62 | +0.54%
 
Earnings

Cytokinetics Announces European Commission Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy. European Commission Approval Based on Results of SEQUOIA-HCM

 

Tue Feb 17, 2026

$66.62 | +0.54%
 
Activity
 
 
 
 
 
StocksRunner

Discover CYTK Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends and the future potential of CYTK. We're here to help you make informed investment decisions today.

 

FIND US ON

StocksRunner on Facebook StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss

 

Receive our CYTK Daily Alerts

Unlock the knowledge that 5,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

 
Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

CYTK Stock trends

CYTK Stock performance

CYTK Stock analysis

CYTK investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner Insights

Financial Reports

 
 

Disclaimer: The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
 
StocksRunner logo
 

CYTK Alerts

Real-time signals powered by data
×

Price-Based

Triggers when the stock breaks through a known resistance level
 
Triggers when the stock drops below a key support level
 
Notifies if the stock moves up/down by a set percentage (e.g. ±5%)
 
Alerts when the stock hits a new high or low
 
Signals proximity to long-term highs or lows (e.g. within 5%)
 

Technical Indicator (Pro Plan)

Volume spikes 2x–3x above average. Indicates strong buying/selling pressure
 
Tracks large intraday swings, signaling potential opportunities or risk
 
Signals potential trend reversals or continuations
 
Long-term bullish/bearish trend signals from MA crossovers
 
RSI above 70 or below 30 to identify possible reversals
 
Signals momentum shifts
 

Fundamental Indicator (Master Plan)

Upcoming or just-released earnings reports
 
Alerts after results compared to expectations
 
Changes in rating or target price
 
New or changed dividends
 
Large trades by company insiders
 
M&A, lawsuits, product launches, etc
 
High volume/open interest in call/put contracts
 
Surge in mentions or sentiment shifts
 
 
Cancel
 
×
 
0/666
joker
 
Post
 
✕
 
StocksRunner logo
 

Don't Be a Sheep, Be a StocksRunner

 

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

 
StocksRunner thumbnail
 
 

Sign up for free and

continue analysing CYTK

 
Signup to Stocksrunner
 

Already a Member? Click here to Login

 

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence and cutting-edge intelligence.

 
✕
 
StocksRunner logo
 

Don't Be a Sheep, Be a StocksRunner

 

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

 
StocksRunner thumbnail
 
 

Sign up for free and

continue analysing CYTK

 
Signup to Stocksrunner
 

Already a Member? Click here to Login

 

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence and cutting-edge intelligence.